The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
Objective To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts. Design Cost‐utility analysis. Set...
Gespeichert in:
| Veröffentlicht in: | BJOG : an international journal of obstetrics and gynaecology 2008-07, Vol.115 (8), p.947-956 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 956 |
|---|---|
| container_issue | 8 |
| container_start_page | 947 |
| container_title | BJOG : an international journal of obstetrics and gynaecology |
| container_volume | 115 |
| creator | Dasbach, EJ Insinga, RP Elbasha, EH |
| description | Objective To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.
Design Cost‐utility analysis.
Setting UK.
Population Female and male UK population 12 years or older.
Methods We adapted a previously developed multi‐HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch‐up vaccination at ages 12–14, 12–17 and 12–24 years.
Main outcomes measures Costs, cases avoided, incremental cost per quality‐adjusted life year (QALY).
Results The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18‐related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12‐ to 24‐year‐old catch‐up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost‐effectiveness ratios across all strategies ranged from £5882 to £11,412 per QALY gained.
Conclusion In the UK, a quadrivalent HPV vaccination programme that includes a catch‐up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost‐effective. |
| doi_str_mv | 10.1111/j.1471-0528.2008.01743.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69346945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20919784</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4553-4c1c0c16e7656412ccbf4f59d7ad1ce06d6f84b724b2febbf873a78df0273f833</originalsourceid><addsrcrecordid>eNqNkctu1DAUQCMEoqXwC8hCAsEi6fXbWbCAinelbtq15Tg29ciJ03gytH-P0xkViQ14YV_J5750qgphaHA5p5sGM4lr4EQ1BEA1gCWjze2j6vjh4_F9DDVQoo6qZzlvALAgQJ9WR1hxoFyy42q4vHbITaF3Q0gx_QzWRGTGHjmbxjQEi8IwGbtFySODbhbTz2Fnohu36HoZzIgmM4UY02B2YV4y2hlrw-jQW3Fa5sTlVu9QGNG2tLn68bx64k3M7sXhPamuPn-6PPtan198-Xb24by2jHNaM4stWCycFFwwTKztPPO87aXpsXUgeuEV6yRhHfGu67yS1EjVeyCSekXpSfVmX3ea083i8lYPIVsXoxldWrIWLWWiZfyfIIEWt1KxAr76C9ykZR7LEpoQLgCkFAVSe8jOKefZeT3NYTDzncagV3F6o1c_evWjV3H6Xpy-LakvD_WXbnD9n8SDqQK8PgAmF0d-NqMN-YEjwIho-brR-z33K0R3998D6I_fL9aI_gZdGLGV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225600776</pqid></control><display><type>article</type><title>The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Dasbach, EJ ; Insinga, RP ; Elbasha, EH</creator><creatorcontrib>Dasbach, EJ ; Insinga, RP ; Elbasha, EH</creatorcontrib><description>Objective To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.
Design Cost‐utility analysis.
Setting UK.
Population Female and male UK population 12 years or older.
Methods We adapted a previously developed multi‐HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch‐up vaccination at ages 12–14, 12–17 and 12–24 years.
Main outcomes measures Costs, cases avoided, incremental cost per quality‐adjusted life year (QALY).
Results The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18‐related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12‐ to 24‐year‐old catch‐up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost‐effectiveness ratios across all strategies ranged from £5882 to £11,412 per QALY gained.
Conclusion In the UK, a quadrivalent HPV vaccination programme that includes a catch‐up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost‐effective.</description><identifier>ISSN: 1470-0328</identifier><identifier>EISSN: 1471-0528</identifier><identifier>DOI: 10.1111/j.1471-0528.2008.01743.x</identifier><identifier>PMID: 18503574</identifier><identifier>CODEN: BIOGFQ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Cervical cancer ; Cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - economics ; Cervical Intraepithelial Neoplasia - epidemiology ; Cervical Intraepithelial Neoplasia - prevention & control ; Condylomata Acuminata - economics ; Condylomata Acuminata - epidemiology ; Condylomata Acuminata - prevention & control ; Cost-Benefit Analysis ; cost‐effectiveness analysis ; Disease prevention ; economics ; Epidemiology ; Female ; Gynecology ; Gynecology. Andrology. Obstetrics ; Health economics ; Human papillomavirus ; Humans ; Incidence ; Male ; Mass Screening - economics ; Medical sciences ; Papillomavirus Vaccines ; Quality-Adjusted Life Years ; United Kingdom - epidemiology ; uterine cervical neoplasms ; Uterine Cervical Neoplasms - economics ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - prevention & control ; Vaccines</subject><ispartof>BJOG : an international journal of obstetrics and gynaecology, 2008-07, Vol.115 (8), p.947-956</ispartof><rights>2008 Merck & Co., Inc. Journal compilation © RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecology</rights><rights>2008 INIST-CNRS</rights><rights>Journal compilation © RCOG 2008 BJOG An International Journal of Obstetrics and Gynaecology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4553-4c1c0c16e7656412ccbf4f59d7ad1ce06d6f84b724b2febbf873a78df0273f833</citedby><cites>FETCH-LOGICAL-c4553-4c1c0c16e7656412ccbf4f59d7ad1ce06d6f84b724b2febbf873a78df0273f833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1471-0528.2008.01743.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1471-0528.2008.01743.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20426955$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18503574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dasbach, EJ</creatorcontrib><creatorcontrib>Insinga, RP</creatorcontrib><creatorcontrib>Elbasha, EH</creatorcontrib><title>The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK</title><title>BJOG : an international journal of obstetrics and gynaecology</title><addtitle>BJOG</addtitle><description>Objective To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.
Design Cost‐utility analysis.
Setting UK.
Population Female and male UK population 12 years or older.
Methods We adapted a previously developed multi‐HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch‐up vaccination at ages 12–14, 12–17 and 12–24 years.
Main outcomes measures Costs, cases avoided, incremental cost per quality‐adjusted life year (QALY).
Results The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18‐related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12‐ to 24‐year‐old catch‐up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost‐effectiveness ratios across all strategies ranged from £5882 to £11,412 per QALY gained.
Conclusion In the UK, a quadrivalent HPV vaccination programme that includes a catch‐up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost‐effective.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cervical cancer</subject><subject>Cervical intraepithelial neoplasia</subject><subject>Cervical Intraepithelial Neoplasia - economics</subject><subject>Cervical Intraepithelial Neoplasia - epidemiology</subject><subject>Cervical Intraepithelial Neoplasia - prevention & control</subject><subject>Condylomata Acuminata - economics</subject><subject>Condylomata Acuminata - epidemiology</subject><subject>Condylomata Acuminata - prevention & control</subject><subject>Cost-Benefit Analysis</subject><subject>cost‐effectiveness analysis</subject><subject>Disease prevention</subject><subject>economics</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health economics</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Mass Screening - economics</subject><subject>Medical sciences</subject><subject>Papillomavirus Vaccines</subject><subject>Quality-Adjusted Life Years</subject><subject>United Kingdom - epidemiology</subject><subject>uterine cervical neoplasms</subject><subject>Uterine Cervical Neoplasms - economics</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - prevention & control</subject><subject>Vaccines</subject><issn>1470-0328</issn><issn>1471-0528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctu1DAUQCMEoqXwC8hCAsEi6fXbWbCAinelbtq15Tg29ciJ03gytH-P0xkViQ14YV_J5750qgphaHA5p5sGM4lr4EQ1BEA1gCWjze2j6vjh4_F9DDVQoo6qZzlvALAgQJ9WR1hxoFyy42q4vHbITaF3Q0gx_QzWRGTGHjmbxjQEi8IwGbtFySODbhbTz2Fnohu36HoZzIgmM4UY02B2YV4y2hlrw-jQW3Fa5sTlVu9QGNG2tLn68bx64k3M7sXhPamuPn-6PPtan198-Xb24by2jHNaM4stWCycFFwwTKztPPO87aXpsXUgeuEV6yRhHfGu67yS1EjVeyCSekXpSfVmX3ea083i8lYPIVsXoxldWrIWLWWiZfyfIIEWt1KxAr76C9ykZR7LEpoQLgCkFAVSe8jOKefZeT3NYTDzncagV3F6o1c_evWjV3H6Xpy-LakvD_WXbnD9n8SDqQK8PgAmF0d-NqMN-YEjwIho-brR-z33K0R3998D6I_fL9aI_gZdGLGV</recordid><startdate>200807</startdate><enddate>200807</enddate><creator>Dasbach, EJ</creator><creator>Insinga, RP</creator><creator>Elbasha, EH</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200807</creationdate><title>The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK</title><author>Dasbach, EJ ; Insinga, RP ; Elbasha, EH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4553-4c1c0c16e7656412ccbf4f59d7ad1ce06d6f84b724b2febbf873a78df0273f833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cervical cancer</topic><topic>Cervical intraepithelial neoplasia</topic><topic>Cervical Intraepithelial Neoplasia - economics</topic><topic>Cervical Intraepithelial Neoplasia - epidemiology</topic><topic>Cervical Intraepithelial Neoplasia - prevention & control</topic><topic>Condylomata Acuminata - economics</topic><topic>Condylomata Acuminata - epidemiology</topic><topic>Condylomata Acuminata - prevention & control</topic><topic>Cost-Benefit Analysis</topic><topic>cost‐effectiveness analysis</topic><topic>Disease prevention</topic><topic>economics</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health economics</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Mass Screening - economics</topic><topic>Medical sciences</topic><topic>Papillomavirus Vaccines</topic><topic>Quality-Adjusted Life Years</topic><topic>United Kingdom - epidemiology</topic><topic>uterine cervical neoplasms</topic><topic>Uterine Cervical Neoplasms - economics</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - prevention & control</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dasbach, EJ</creatorcontrib><creatorcontrib>Insinga, RP</creatorcontrib><creatorcontrib>Elbasha, EH</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dasbach, EJ</au><au>Insinga, RP</au><au>Elbasha, EH</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK</atitle><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle><addtitle>BJOG</addtitle><date>2008-07</date><risdate>2008</risdate><volume>115</volume><issue>8</issue><spage>947</spage><epage>956</epage><pages>947-956</pages><issn>1470-0328</issn><eissn>1471-0528</eissn><coden>BIOGFQ</coden><abstract>Objective To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.
Design Cost‐utility analysis.
Setting UK.
Population Female and male UK population 12 years or older.
Methods We adapted a previously developed multi‐HPV type dynamic transmission to compare four female vaccination strategies, routine vaccination at age 12 years, and routine vaccination at age 12 years combined with temporary catch‐up vaccination at ages 12–14, 12–17 and 12–24 years.
Main outcomes measures Costs, cases avoided, incremental cost per quality‐adjusted life year (QALY).
Results The model projected that at year 100, each vaccination strategy could reduce the number of HPV 6/11/16/18‐related cervical cancer, CIN2/3, CIN1 and genital wart cases among women by 86, 85, 79 and 89% respectively. Over 25 years, routine vaccination at age 12 years combined with a 12‐ to 24‐year‐old catch‐up programme was the most effective strategy, reducing the cumulative number of cases of cervical cancer, CIN2/3, CIN1 and genital warts by 5800, 146 000, 28 000, and 1.1 million respectively. Over 100 years, the incremental cost‐effectiveness ratios across all strategies ranged from £5882 to £11,412 per QALY gained.
Conclusion In the UK, a quadrivalent HPV vaccination programme that includes a catch‐up strategy can reduce the incidence of cervical cancer, CIN and genital warts at a cost per QALY ratio within the range typically regarded as cost‐effective.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18503574</pmid><doi>10.1111/j.1471-0528.2008.01743.x</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-0328 |
| ispartof | BJOG : an international journal of obstetrics and gynaecology, 2008-07, Vol.115 (8), p.947-956 |
| issn | 1470-0328 1471-0528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69346945 |
| source | MEDLINE; Wiley Journals |
| subjects | Adolescent Adult Biological and medical sciences Cervical cancer Cervical intraepithelial neoplasia Cervical Intraepithelial Neoplasia - economics Cervical Intraepithelial Neoplasia - epidemiology Cervical Intraepithelial Neoplasia - prevention & control Condylomata Acuminata - economics Condylomata Acuminata - epidemiology Condylomata Acuminata - prevention & control Cost-Benefit Analysis cost‐effectiveness analysis Disease prevention economics Epidemiology Female Gynecology Gynecology. Andrology. Obstetrics Health economics Human papillomavirus Humans Incidence Male Mass Screening - economics Medical sciences Papillomavirus Vaccines Quality-Adjusted Life Years United Kingdom - epidemiology uterine cervical neoplasms Uterine Cervical Neoplasms - economics Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - prevention & control Vaccines |
| title | The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A47%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20epidemiological%20and%20economic%20impact%20of%20a%20quadrivalent%20human%20papillomavirus%20vaccine%20(6/11/16/18)%20in%20the%20UK&rft.jtitle=BJOG%20:%20an%20international%20journal%20of%20obstetrics%20and%20gynaecology&rft.au=Dasbach,%20EJ&rft.date=2008-07&rft.volume=115&rft.issue=8&rft.spage=947&rft.epage=956&rft.pages=947-956&rft.issn=1470-0328&rft.eissn=1471-0528&rft.coden=BIOGFQ&rft_id=info:doi/10.1111/j.1471-0528.2008.01743.x&rft_dat=%3Cproquest_cross%3E20919784%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225600776&rft_id=info:pmid/18503574&rfr_iscdi=true |